Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phaseI trial in rectal cancer patients - Willett, CG; Boucher, Y; Duda, DG (J Clin Oncol, 2005)
et al.